학술논문

Health-related quality-of-life analyses from a multicenter, randomized, double-blind phase 2 study of patients with differentiated thyroid cancer treated with lenvatinib 18 or 24 mg/day
Document Type
Article
Source
In: Cancer Medicine. (Cancer Medicine, February 2023, 12(4):4332-4342)
Subject
Language
English
ISSN
20457634